Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?
10.3803/EnM.2020.35.2.206
- Author:
Cheol Ryong KU
1
;
Vladimir MELNIKOV
;
Zhaoyun ZHANG
;
Eun Jig LEE
Author Information
1. Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- Publication Type:Review Article
- From:Endocrinology and Metabolism
2020;35(2):206-216
- CountryRepublic of Korea
- Language:0
-
Abstract:
Acromegaly presents with an enigmatic range of symptoms and comorbidities caused by chronic and progressive growth hormone elevations, commonly due to endocrinologic hypersecretion from a pituitary gland tumor. Comprehensive national acromegaly databases have been appearing over the years, allowing for international comparisons of data, although still presenting varying prevalence and incidence rates. Lack of large-scale analysis in geographical and ethnic differences in clinical presentation and management requires further research. Assessment of current and novel predictors of responsiveness to distinct therapy can lead to multilevel categorization of patients, allowing integration into new clinical guidelines and reduction of increased morbidity and mortality associated with acromegaly. This review compares current data from epidemiological studies and assesses the present-day application of prognostic factors in medical practice, the reality of precision therapy, as well as its future prospects in acromegaly, with a special focus on its relevance to the South Korean population.
